adenovirus

TWiV 655: Minority health with Robert Fullilove

Sociomedical scientist Robert Fullilove joins TWiV to discuss disparities in minority health; FDA announces an EUA on Yale’s SalivaDirect, protection of the upper and respiratory tract of mice after intranasal inoculation with an adenovirus-vectored SARS-CoV-2 spike gene, and listener questions. Click arrow to playDownload TWiV 655 (88 MB .mp3, 147 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show …

TWiV 655: Minority health with Robert Fullilove Read More »

Preliminary phase I/II results of ChAdOx1 SARS-CoV-2 vaccine

by Gertrud U. Rey On July 20, 2020, Oxford University’s Jenner Institute and the pharmaceutical company AstraZeneca reported preliminary results from phase I/II clinical trials assessing the safety and efficacy of a vaccine candidate against SARS-CoV-2.  The vaccine candidate, named AZD1222 (referred to in the publication as ChAdOx1 nCoV-19), consists of an adenovirus vector with an …

Preliminary phase I/II results of ChAdOx1 SARS-CoV-2 vaccine Read More »

TWiV 634: 1000 hours of the sunlight of TWiV

TWiV reviews a new H1N1 swine influenza virus from China with pandemic potential, Ad5 vectored SARS-CoV-2 oral vaccine candidate, Operation Warp Speed vaccine candidates, FDA guidance on vaccine approval, and answer listener email. Click arrow to playDownload TWiV 634 (72 MB .mp3, 120 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv

Complementing neutralization of viruses by antibodies

Viral infection of vertebrates leads to the production of antibodies, and some of these can block virus infection by a process that is called neutralization. Antibodies can neutralize viral infectivity in a number of ways: they may impair virus entry into cells, and even cause degradation of the capsid in the cytoplasm. A newly discovered …

Complementing neutralization of viruses by antibodies Read More »

Scroll to Top